Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

Long-term daclizumab therapy in relapsing-remitting multiple sclerosis.
Untargeted plasma metabolomics identifies endogenous metabolite with drug-like properties in chronic animal model of multiple sclerosis.
Discontinuation of Disease-Modifying Treatment for Multiple Sclerosis
Clinical relevance of differential lymphocyte recovery after alemtuzumab therapy for multiple sclerosis.
Rituximab in paediatric onset multiple sclerosis: a case series.
Lesion morphology at 7 Tesla MRI differentiates Susac syndrome from multiple sclerosis.
Mitoxantrone-induced suicidal erythrocyte death.
Analysis of Onset Mechanisms of a Sphingosine 1-Phosphate Receptor Modulator Fingolomod-Induced Atrioventricular Conduction Block and QT-Interval Prolongation.
Receptos Completes Enrollment of RADIANCE Phase 3 Trial of Ozanimod in Relapsing Multiple Sclerosis
Persistence on therapy and propensity matched outcome comparison of two subcutaneous interferon Beta 1a dosages for multiple sclerosis.
Altered likelihood of brain activation in attention and working memory networks in patients with multiple sclerosis: An ALE meta-analysis.
Astaxanthin as a Potential Neuroprotective Agent for Neurological Diseases.
Pathological mechanisms in progressive multiple sclerosis.
Evaluating the response to glatiramer acetate in relapsing-remitting multiple sclerosis (RRMS) patients.
Population pharmacokinetics of daclizumab high-yield process in healthy volunteers: integrated analysis of intravenous and subcutaneous, single- and multiple-dose administration.
FDA denies Teva Copaxone generic trials petition
Prospective Observational Long-term Safety Registry of Multiple Sclerosis Patients Who Have Participated in Cladribine Clinical Trials
[The first experience of the use the Russian Β-interferon-1b biosimilar (infibeta) in the daily practice of the Moscow Center of Multiple Sclerosis.]
Glatiramer acetate during early pregnancy: A prospective cohort study.
Study to evaluate early glatiramer acetate treatment in delaying conversion to CDMS of subjects presenting with CIS (PreCISe)
Better Prognosis of Multiple Sclerosis in Patients Who Experienced a Full-Term Pregnancy.
Cross-sectional study assessing long-term safety of interferon-beta-1b for relapsing-remitting MS.
Biogen Idec and Abbott Announce Positive Top-Line Results from the First Registrational Trial for Daclizumab HYP in relapsing-Remitting Multiple Sclerosis
Receptos initiates clinical trials for S1P1 agonist program, aimed at multiple sclerosis
[Neuromyelitis optica following thymectomy with severe spinal cord atrophy after frequent relapses for 30 years].

Pages